- Home
- GLQ vs CHRS Comparison
GLQ vs CHRS Comparison
Compare GLQ & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLQ
- CHRS
- Stock Information
- Founded
- GLQ 2005
- CHRS 2010
- Country
- GLQ United States
- CHRS United States
- Employees
- GLQ N/A
- CHRS N/A
- Industry
- GLQ Finance/Investors Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLQ Finance
- CHRS Health Care
- Exchange
- GLQ Nasdaq
- CHRS Nasdaq
- Market Cap
- GLQ 119.5M
- CHRS 112.5M
- IPO Year
- GLQ N/A
- CHRS 2014
- Fundamental
- Price
- GLQ $6.83
- CHRS $0.77
- Analyst Decision
- GLQ
- CHRS Buy
- Analyst Count
- GLQ 0
- CHRS 3
- Target Price
- GLQ N/A
- CHRS $4.68
- AVG Volume (30 Days)
- GLQ 65.5K
- CHRS 1.5M
- Earning Date
- GLQ 01-01-0001
- CHRS 05-12-2025
- Dividend Yield
- GLQ 11.11%
- CHRS N/A
- EPS Growth
- GLQ N/A
- CHRS N/A
- EPS
- GLQ N/A
- CHRS N/A
- Revenue
- GLQ N/A
- CHRS $272,251,000.00
- Revenue This Year
- GLQ N/A
- CHRS N/A
- Revenue Next Year
- GLQ N/A
- CHRS $19.78
- P/E Ratio
- GLQ N/A
- CHRS N/A
- Revenue Growth
- GLQ N/A
- CHRS 19.87
- 52 Week Low
- GLQ $5.13
- CHRS $0.66
- 52 Week High
- GLQ $6.54
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- GLQ 67.76
- CHRS 39.79
- Support Level
- GLQ $6.67
- CHRS $0.74
- Resistance Level
- GLQ $6.77
- CHRS $0.82
- Average True Range (ATR)
- GLQ 0.09
- CHRS 0.06
- MACD
- GLQ -0.00
- CHRS -0.00
- Stochastic Oscillator
- GLQ 100.00
- CHRS 25.45
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.